Alexion Reports Prelim. Data from Study on Eculizumab Shows Potential Effectiveness for Acute AMR

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that researchers have presented preliminary data from a single-arm Phase 2 study of eculizumab (Soliris^®) as an investigational therapy to prevent acute antibody-mediated rejection (AMR) in sensitized deceased-donor kidney transplant recipients. The composite primary endpoint was the nine-week occurrence of post-transplantation treatment failure, which occurred in